News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Diabetes, Infectious Diseases Early Focus of San Antonio Biomed Plan

David Holley, Xconomy Texas —  San Antonio — [Updated 12/14/17, 11:54 p.m. See below.] ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
Invictus Medical appoints Dennis P. Kane to Board of Directors
February 6, 2015

(SAN ANTONIO, Texas) - Invictus Medical, the San Antonio, Texas-based medical device company dedicated to providing newborns with healthy early developmental milestones, has appointed Mr. Dennis P. Kane to its Board of Directors. Kane brings more than 35 years of medical technology experience to the Invictus board.

"Mr. Kane adds depth to our marketing and sales expertise, and a track record of accomplishment in the commercialization of medical devices," said Tom Roberts, Invictus Medical President and CEO. "Additionally, the breadth of his understanding of the global marketplace for medical technologies, and his passion for innovation, will aid us greatly in advancing our future pipeline of neonatal care solutions."

Kane's background includes expertise in the global sales and marketing of devices, pharmaceuticals and diagnostics, including global and U.S. sales and marketing at Phadia AB (formerly Pharmacia Diagnostics). Responsible for building and expanding operations related to disease management and pharmacoeconomics, he was with Upjohn, Inc. prior to its merger with Pharmacia.

"Joining the Invictus Medical board is exciting for me because the company is so focused on helping newborns achieve healthy early development milestones," Kane said. "That focus, exemplified by the GELShieldTM, has the potential to change the lives of so many children and their caregivers for the better. I can't think of a more important mission."

Invictus Medical is nearing the commercial launch of its first product, the GELShield, an extracranial pressure relief device, following clearance by the Food and Drug Administration. The company recently closed its Series A round of funding at approximately $3.8 million. The company anticipates securing its Series B funding round in the third quarter of 2015.

Kane was previously Vice President, Global Sales and Marketing, for Phadia AB, a worldwide company selling reagents and systems for serologic testing in the fields of allergy and autoimmune diseases. Thermo Fisher Scientific acquired Phadia for $3.5B in 2011. Kane had previously served as Vice President, U.S. Sales and Marketing, at Phadia, and was responsible for the successful creation, development, and execution of the U.S. primary care expansion strategy of bringing allergy testing into the primary care setting.

Kane serves on the Board of Directors of Aerocrine AB, a Swedish company that markets instruments worldwide for the measurement of nitric oxide. He is also on the Board of Directors of Armune Bioscience, Inc., a U.S. company developing novel new biomarkers for oncology.

About Invictus Medical
Invictus Medical is a San Antonio, Texas-based medical device company that aims to ensure that children are able to attain their developmental milestones. As evidenced by their award-winning innovations, Invictus Medical has been at the forefront of pediatric care since its founding in 2012. Invictus Medical is a privately held company. For more information about Invictus Medical, please see www.invictusmed.com.

Stay informed. Subscribe to BioMed SA news alerts.